A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy
Latest Information Update: 30 Dec 2024
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Therapeutic Use
- Sponsors Amryt Pharma
Most Recent Events
- 15 Jul 2024 New trial record